<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02622763</url>
  </required_header>
  <id_info>
    <org_study_id>TolDec-CD-intra</org_study_id>
    <secondary_id>2014-001083-35</secondary_id>
    <nct_id>NCT02622763</nct_id>
  </id_info>
  <brief_title>Intralesional Tolerogenic Dendritic Cells in Crohn's Disease Treatment</brief_title>
  <acronym>TolDecCDintra</acronym>
  <official_title>Safety and Clinical Efficacy Evaluation of Intralesional Administration of Tolerogenic Dendritic Cells in Patients With Refractory Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion Clinic per a la Recerca Biomédica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Clinic per a la Recerca Biomédica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intralesional Tolerogenic Dendritic Cells in Crohn's Disease Treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective is to evaluate the safety and clinical response of intralesional injection
      of Autologous peripheral blood differentiated adult dendritic cells expanded tolerogenic in
      patients with refractory Crohn's disease treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>from inclusion up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with clinical response defined as a decrease of Crohn 's Disease Activity Index &gt; 100 points</measure>
    <time_frame>up to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with clinical response defined as a decrease of Crohn 's Disease Activity Index &gt; 100 points</measure>
    <time_frame>from baseline to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients in clinical remission defined as Crohn 's Disease Activity Index &lt; 150 points</measure>
    <time_frame>at week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic lesions using the Crohn 's Disease Endoscopic Index of Severity &quot;. Endoscopic remission was defined as the absence of ulcers</measure>
    <time_frame>at baseline and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The evaluation of quality of life will be held by Inflammatory bowel disease questionnaire Immunological endpoints</measure>
    <time_frame>Change from baseline to week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>10 millions dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a total of 10 millions tolerogenic dendritic cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 millions dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a total of 100 millions tolerogenic dendritic cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tolerogenic Dendritic Cells</intervention_name>
    <description>Intralesional administration</description>
    <arm_group_label>10 millions dose</arm_group_label>
    <arm_group_label>100 millions dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed diagnosis of Crohn's disease ( Lennard -Jones criteria )

          2. Active Crohn's disease in the last six months to the inclusion defined as : CDAI? 220
             and endoscopic or radiological criteria of activity

          3. Refractory or intolerance to conventional therapy including corticosteroids ,
             immunomodulators and anti-tumor necrosis factor-alpha

          4. Presence of visible lesions by endoscopy

          5. Acceptance to participate in the study and written informed consent

        Exclusion Criteria:

          1. No injuries in pre-screening resonance

          2. Pregnancy, lactation or women of childbearing age not taking appropriate contraceptive
             measures

          3. Patients HIV + and Hepatitis C Virus + Hepatitis B Virus +

          4. Serious concomitant disease:

               -  Renal failure with creatinine clearance &lt; 40ml / min

               -  Heart disease: congestive heart failure with ejection fraction &lt; 45 % , atrial
                  fibrillation treated with oral anticoagulants, uncontrolled ventricular
                  arrhythmias , pericarditis , pleural effusion with hemodynamic

               -  Neoplasms or myelodysplasia

               -  Psychiatric disorders including alcohol and drugs

          5. Symptoms attributable to fibrotic strictures in Crohn's disease at the discretion of
             the investigators

          6. Diarrhea attributable to &quot; short bowel syndrome&quot;

          7. Active infection , including tuberculosis

          8. Participation in research studies of new drugs in the 3 months prior to inclusion.

          9. Vaccination with live/attenuated germs in the previous 3 months

         10. Personal history of cancer (active or complete remission) or known family history of
             hereditary cancer.

         11. Patients in whom , after observation of the state of their veins , these are
             considered inaccessible and impossible to perform apheresis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elena Ricart, MD PhD</last_name>
    <email>ERICART@clinic.ub.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clinic of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Varea, BS (Biology)</last_name>
      <phone>+34932275400</phone>
      <phone_ext>3343</phone_ext>
      <email>svarea@clinic.ub.es</email>
    </contact>
    <contact_backup>
      <last_name>Daniel Benitez, BS (Biology) PhD</last_name>
      <email>DBENITEZ@clinic.ub.es</email>
    </contact_backup>
    <investigator>
      <last_name>Elena Ricart, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2015</study_first_submitted>
  <study_first_submitted_qc>December 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2015</study_first_posted>
  <last_update_submitted>June 21, 2017</last_update_submitted>
  <last_update_submitted_qc>June 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion Clinic per a la Recerca Biomédica</investigator_affiliation>
    <investigator_full_name>Sara Varea</investigator_full_name>
    <investigator_title>Clinical Research Manager</investigator_title>
  </responsible_party>
  <keyword>Tolerogenic Dendritic Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

